Nuvalent (NUVL) Projected to Post Quarterly Earnings on Thursday

Key Points

• Nuvalent is set to release its Q2 2025 earnings on Thursday, August 14th, with analysts expecting a loss of ($1.27) per share, following a recent quarter where it reported ($1.18) EPS, missing estimates.
• The company's stock has been given multiple buy ratings from analysts, with an average price target of $119.60 and upgrades from institutions including Goldman Sachs and Leerink Partners.
• Insider trading activity included significant sales by CEO James Richard Porter and insider Henry E. Pelish, with insiders collectively selling 85,645 shares in the last ninety days.

Nuvalent (NASDAQ:NUVL - Get Free Report) is expected to be releasing its Q2 2025 earnings data before the market opens on Thursday, August 7th. Analysts expect the company to announce earnings of ($1.27) per share for the quarter.

Nuvalent (NASDAQ:NUVL - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported ($1.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.27) by ($0.04). During the same quarter in the prior year, the business posted ($0.88) EPS. On average, analysts expect Nuvalent to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Nuvalent Price Performance

Shares of Nuvalent stock traded up $1.95 during trading on Friday, reaching $74.11. 891,894 shares of the company traded hands, compared to its average volume of 495,662. Nuvalent has a 1-year low of $55.53 and a 1-year high of $113.51. The company has a 50 day moving average price of $78.99 and a 200-day moving average price of $76.18. The firm has a market capitalization of $5.32 billion, a PE ratio of -15.12 and a beta of 1.30.

Insider Activity at Nuvalent

In related news, CEO James Richard Porter sold 27,000 shares of the stock in a transaction on Tuesday, July 15th. The stock was sold at an average price of $82.27, for a total value of $2,221,290.00. Following the completion of the sale, the chief executive officer directly owned 249,062 shares of the company's stock, valued at approximately $20,490,330.74. This represents a 9.78% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Henry E. Pelish sold 5,500 shares of the stock in a transaction on Thursday, August 7th. The shares were sold at an average price of $74.85, for a total value of $411,675.00. Following the completion of the sale, the insider directly owned 60,956 shares of the company's stock, valued at $4,562,556.60. The trade was a 8.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 91,145 shares of company stock valued at $7,419,532. 10.20% of the stock is owned by insiders.

Institutional Investors Weigh In On Nuvalent

A number of institutional investors and hedge funds have recently bought and sold shares of NUVL. Goldman Sachs Group Inc. raised its position in Nuvalent by 54.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 453,620 shares of the company's stock valued at $32,171,000 after buying an additional 159,873 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Nuvalent by 8.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 149,941 shares of the company's stock valued at $10,634,000 after purchasing an additional 12,123 shares during the last quarter. Intech Investment Management LLC increased its position in shares of Nuvalent by 28.7% during the 1st quarter. Intech Investment Management LLC now owns 19,262 shares of the company's stock valued at $1,366,000 after purchasing an additional 4,293 shares during the last quarter. Finally, AQR Capital Management LLC increased its position in shares of Nuvalent by 64.8% during the 1st quarter. AQR Capital Management LLC now owns 9,874 shares of the company's stock valued at $700,000 after purchasing an additional 3,881 shares during the last quarter. 97.26% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. Robert W. Baird boosted their target price on shares of Nuvalent from $105.00 to $112.00 and gave the company an "outperform" rating in a research report on Wednesday, June 25th. Wedbush reiterated an "outperform" rating and set a $115.00 target price on shares of Nuvalent in a research report on Monday, July 21st. Leerink Partners increased their target price on Nuvalent from $125.00 to $140.00 and gave the stock an "outperform" rating in a report on Tuesday, June 24th. HC Wainwright reiterated a "buy" rating and issued a $130.00 target price (up from $110.00) on shares of Nuvalent in a report on Tuesday, June 24th. Finally, The Goldman Sachs Group upgraded Nuvalent to a "strong-buy" rating in a report on Monday, June 30th. Ten investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $119.60.

About Nuvalent

Nuvalent, Inc, a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial.